As such, it does not invalidate the potential involvement of TGF-β, IFN-α/β and NRF2 pathways, but demonstrates that Usp15 deletion did not impact epilepsy outcomes under the conditions of our experimental setting. This evidence concerns the gene NFE2L2 and epilepsy.